Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 13/2001

01-11-2001 | Current Opinion

Role of Erythromycin for Treatment of Incipient Chronic Lung Disease in Preterm Infants Colonised with Ureaplasma urealyticum

Authors: Dr Christoph Bührer, Thomas Hoehn, Juliane Hentschel

Published in: Drugs | Issue 13/2001

Login to get access

Abstract

Ureaplasma urealyticum is frequently isolated from tracheal aspirates of very low birthweight infants who go on to develop chronic lung disease. The use of erythromycin has been advocated in ventilated very low birthweight infants who are colonised with U. urealyticum, although the association between U. urealyticum and chronic lung disease remains controversial. There are only two randomised, controlled trials involving a total of 37 U. urealyticum-positive very low birthweight infants. Both trials failed to demonstrate a reduction in the incidence of chronic lung disease after 7 or 10 days of erythromycin. On the other hand, there are reports of rare but serious adverse effects of erythromycin in newborn infants including sudden cardiovascular compromise and hypertrophic pyloric stenosis. We conclude that, at present, there is insufficient evidence to support the use of erythromycin for the treatment of incipient chronic lung disease in very low birthweight infants colonised with U. urealyticum.
Literature
1.
Young TE, Kruyer LS, Marshall DD, et al. Population-based study of chronic lung disease in very low birthweight infants in North Carolina in 1994 with comparisons with 1984. The North Carolina Neonatologists Association. Pediatrics 1999; 104: el7CrossRef
2.
Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. Eur J Pediatr 1999; 158 Suppl. l: S18–22PubMedCrossRef
3.
Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics 2000; 105: 1216–26PubMedCrossRef
4.
Blanchard A, Hentschel J, Duffy L, et al. Detection of ureaplasma urealyticum by polymerase chain reaction in the urogenital tract of adults, in amniotic fluid, and in the respiratory tract of newborns. Clin Infect Dis 1993; 17 Suppl. l: S148–53PubMedCrossRef
5.
Cunliffe NA, Fergusson S, Davidson F, et al. Comparison of culture with the polymerase chain reaction for detection of ureaplasma urealyticum in endotracheal aspirates of preterm infants. J Med Microbiol 1996; 45: 27–30PubMedCrossRef
6.
Abele-Horn M, Wolff C, Dressel P, et al. Polymerase chain reaction versus culture for detection of Ureaplasma urealyticum and Mycoplasma hominis in the urogenital tract of adults and the respiratory tract of newborns. Eur J Clin Microbiol Infect Dis 1996; 15: 595–8PubMedCrossRef
7.
Nelson S, Matlow A, Johnson G, et al. Detection of ureaplasma urealyticum in endotracheal tube aspirates from neonates by PCR. J Clin Microbiol 1998; 36: 1236–9PubMed
8.
Luki N, Lebel P, Boucher M, et al. Comparison of polymerase chain reaction assay with culture for detection of genital mycoplasmas in perinatal infection. Eur J Clin Microbiol Infect Dis 1998; 17: 255–63PubMed
9.
Cassell GH, Waites KB, Crouse DT, et al. Association of ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet 1988; 332: 240–5CrossRef
10.
Wang EE, Frayha H, Watts J, et al. Role of ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity. Pediatr Infect Dis J 1988; 7: 547–51PubMed
11.
Sanchez PJ, Regan JA. Ureaplasma urealyticum colonization and chronic lung disease in low birth weight infants. Pediatr Infect Dis J 1988; 7: 542–6PubMed
12.
Wang EE, Ohlsson A, Kellner JD. Association of ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr 1995; 127: 640–4PubMedCrossRef
13.
Iles R, Lyon A, Ross P, McIntosh N. Infection with ureaplasma urealyticum and mycoplasma hominis and the development of chronic lung disease in preterm infants. Acta Paediatr 1996; 85: 482–4PubMedCrossRef
14.
Garland SM, Bowman ED. Role of ureaplasma urealyticum and chlamydia trachomatis in lung disease in low birth weight infants. Pathology 1996; 28: 266–9PubMedCrossRef
15.
Da Silva O, Gregson D, Hammerberg O. Role of ureaplasma urealyticum and chlamydia trachomatis in development of bronchopulmonary dysplasia in very low birth weight infants. Pediatr Infect Dis J 1997; 16: 364–9PubMedCrossRef
16.
van Waarde WM, Brus F, Okken A, et al. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J 1997; 10: 886–90PubMed
17.
Pacifico L, Panero A, Roggini M, et al. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997; 16: 579–86PubMedCrossRef
18.
Perzigian RW, Adams JT, Weiner GM, et al. Ureaplasma urealyticum and chronic lung disease in very low birth weight infants during the exogenous surfactant era. Pediatr Infect Dis J 1998; 17: 620–5PubMedCrossRef
19.
Abele-Horn M, Genzel-Boroviczeny O, Uhlig T, et al. Ureaplasma urealyticum colonization and bronchopulmonary dysplasia: a comparative prospective multicentre study. Eur J Pediatr 1998; 157: 1004–11PubMedCrossRef
20.
Ollikainen J, Heiskanern-Kos T, Korppi M, et al. Clinical relevance of Ureaplasma urealyticum colonization in preterm infants. Acta Paediatr 1998; 87: 1075–8PubMedCrossRef
21.
Hannaford K, Todd DA, Jeffery H, et al. Role of ureaplasma urealyticum in lung disease of prematurity. Arch Dis Child 1999; 81: F162–7
22.
Couroucli XI, Welty SE, Ramsay PL, et al. Detection of microorganisms in the trachéal aspirates of preterm infants by polymerase chain reaction: association of adenovirus infection with bronchopulmonary dysplasia. Pediatr Res 2000; 47: 225–32PubMedCrossRef
23.
Smyth AR, Shaw NJ, Pratt BC, et al. Ureaplasma urealyticum and chronic lung disease. Eur J Pediatr 1993; 152: 931–2PubMedCrossRef
24.
Jónsson B, Karell AC, Ringertz S, et al. Neonatal Ureaplasma urealyticum colonization and chronic lung disease. Acta Paediatr 1994; 83: 927–30PubMedCrossRef
25.
Löffler F. Untersuchungen über die Bedeutung der Mikroorganismen für die Entstehung der Diphtherie beim Menschen, bei der Taube und beim Kalbe. Mittheilungen aus dem Kaiserlichen Gesundheitsamte 1884; 2: 421–49
26.
Crouse DT, Cassell GH, Waites KB, et al. Hyperoxia potentiates ureaplasma urealyticum pneumonia in newborn mice. Infect Immun 1990; 58: 3487–93PubMed
27.
28.
Abele-Horn M, Becher C, Bauernfeind A, et al. Comparative in vitro susceptibility of ureaplasma urealyticum and mycoplasma hominis to macrolides, tetracyclines, 4-quinolones, chloramphenicol, gentamicin, and clindamycin. Antiinfect Drugs Chemother 1996; 14: 171–3
29.
Matlow A, Th’ng C, Kovach D, et al. Susceptibilities of neonatal respiratory isolates of Ureaplasma urealyticum to antimicrobial agents. Antimicrob Agents Chemother 1998; 42: 1290–2PubMed
30.
Waites KB, Crouse DT, Cassell GH. Antibiotic susceptibilities and therapeutic options for Ureaplasma urealyticum infections in neonates. Pediatr Infect Dis J 1992; 11: 23–9PubMedCrossRef
31.
Waites KB, Crouse DT, Cassell GH. Therapeutic considerations for Ureaplasma urealyticum infections in neonates. Clin Infect Dis 1993; 17 Suppl. 1: S208–14PubMedCrossRef
32.
Waites KB, Sims PJ, Crouse DT, et al. Serum concentrations of erythromycin after intravenous infusion in preterm neonates treated for ureaplasma urealyticum infection. Pediatr Infect Dis J 1994; 13: 287–93PubMedCrossRef
33.
Bowman ED, Dharmalingam A, Fan WQ, et al. Impact of eryth-romycin on respiratory colonization of ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants. Pediatr Infect Dis J 1998; 17: 615–20PubMedCrossRef
34.
Heggie AD, Jacobs MR, Butler VT, et al. Frequency and significance of isolation of ureaplasma urealyticum and mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants. J Pediatr 1994; 124: 956–61PubMedCrossRef
35.
Lyon AJ, McColm J, Middlemist L, et al. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child 1998; 78: F10–4
36.
Jónsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high-risk preterm neonates. Acta Paediatr 1998; 87: 1079–84PubMedCrossRef
37.
Farrar HC, Walsh Sukys MC, Kyllonen K, Blumer JL. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993; 12: 688–91PubMedCrossRef
38.
Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999; 354: 2101–5PubMedCrossRef
39.
40.
Eschenbach DA, Nugent RP, Rao AV, et al. A randomized placebo-controlled trial of erythromycin for the treatment of ureaplasma urealyticum to prevent premature delivery. The Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol 1991; 164: 734–42
41.
Ogasawara KK, Goodwin TM. The efficacy of prophylactic erythromycin in preventing vertical transmission of ureaplasma urealyticum. Am J Perinatol 1997; 14: 233–7PubMedCrossRef
42.
Kenyon SL, Taylor DJ, Tarnow-Mordi W, et al. Broad spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet 2001; 357: 978–88CrossRef
43.
Kenyon SL, Taylor DJ, Tarnow-Mordi W, et al. Broad spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. Lancet 2001; 357: 989–94PubMedCrossRef
Metadata
Title
Role of Erythromycin for Treatment of Incipient Chronic Lung Disease in Preterm Infants Colonised with Ureaplasma urealyticum
Authors
Dr Christoph Bührer
Thomas Hoehn
Juliane Hentschel
Publication date
01-11-2001
Publisher
Springer International Publishing
Published in
Drugs / Issue 13/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200161130-00002

Other articles of this Issue 13/2001

Drugs 13/2001 Go to the issue

Review Article

Pregnancy and Renal Failure

Therapy in Practice

Cervical Dystonia

Adis Drug Evaluation

Cyclosporin

Therapy in Practice

Current Management of Primary Pulmonary Hypertension

Leading Article

Role of ACE Inhibitors in Patients with Diabetes Mellitus